Bridgebio Pharma
Stock
Stock
ISIN: US10806X1028
Ticker: BBIO
US10806X1028
BBIO
Price
Price
CHART BY
Frequently asked questions
What is Bridgebio Pharma's market capitalization?
The market capitalization of Bridgebio Pharma is $5.01B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Bridgebio Pharma?
Bridgebio Pharma's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.412. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Bridgebio Pharma's stock?
Currently, 17 analysts cover Bridgebio Pharma's stock, with a consensus target price of $49.43. Analyst ratings provide insights into the stock's expected performance.
What is Bridgebio Pharma's revenue over the trailing twelve months?
Over the trailing twelve months, Bridgebio Pharma reported a revenue of $217.77M.
What is the EBITDA for Bridgebio Pharma?
Bridgebio Pharma's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$526.40M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Bridgebio Pharma?
Bridgebio Pharma has a free cash flow of -$451.54M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Bridgebio Pharma have, and what sector and industry does it belong to?
Bridgebio Pharma employs approximately 550 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Bridgebio Pharma's shares?
The free float of Bridgebio Pharma is 147.70M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $5.01B
- EPS (TTM)
- -$2.412
- Free Float
- 147.70M
- Revenue (TTM)
- $217.77M
- EBITDA (TTM)
- -$526.40M
- Free Cashflow (TTM)
- -$451.54M
Pricing
- 1D span
- $25.70$26.91
- 52W span
- $21.68$44.18
Analyst Ratings
The price target is $49.43 and the stock is covered by 17 analysts.
Buy
15
Hold
2
Sell
0
Information
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
- Employees
- 550
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US10806X1028
- Primary Ticker
- BBIO